Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia
| Autor: | Debra Kush, Da Yi Hu, Christine McCrary Sisk, Waheeda Sirah, Hyo-Soo Kim, Ji Liu, John F. Paolini, Aditi Sapre, Darbie Maccubbin |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Nutrition and Dietetics
Statin Triglyceride medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Antagonist Pharmacology Placebo behavioral disciplines and activities chemistry.chemical_compound chemistry Concomitant Internal Medicine medicine lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Laropiprant Niacin Lipoprotein |
| Zdroj: | Journal of Clinical Lipidology. 3:179-186 |
| ISSN: | 1933-2874 |
| DOI: | 10.1016/j.jacl.2009.04.048 |
| Popis: | Niacin has proven lipid-modifying efficacy and cardiovascular benefit; however, it is underused because of skin flushing, a process mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that mitigates niacin-induced flushing, has been combined with extended-release niacin (ERN) into a fixed-dose tablet containing 1g of ERN and 20mg of LRPT (ERN/LRPT 1g). In a large-scale (n=∼1600), multinational, 6-month study in dyslipidemic patients, ERN/LRPT 2g produced superior lipid-modifying efficacy vs placebo, whether administered alone or with concomitant statins.This Phase III, randomized, double-blind study evaluated the lipid-modifying efficacy of ERN/LRPT alone or added to ongoing statins in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.After a 4-week placebo run-in, patients were randomized to ERN/LRPT 1g (n=322) or placebo (PBO; n=324). After 4 weeks, the dose was advanced to 2 tablets/d (ERN/LRPT 2g or PBO) for 8 additional weeks. End points included effects of ERN/LRPT 2g vs PBO on low-density lipoprotein cholesterol (LDL-C; primary), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and other lipids/lipoproteins.Relative to PBO, ERN/LRPT 2g produced significant (P.001) changes in LDL-C (-14.7%), HDL-C (15.9%), TG (-23.4%), LDL-C:HDL-C (-25.5%), non-HDL-C (-16.4%), apolipoprotein (Apo) B (-15.4%), and Apo A-I (5.3%) from baseline to week 12 in the total population. Similar results were observed in patients treated with ERN/LRPT alone or added to ongoing statin.ERN/LRPT 2g, administered alone or with a statin, produced significant improvements in multiple lipid/lipoprotein parameters in dyslipidemic Asian patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect